Glaukos/$GKOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Ticker
$GKOS
Sector
Primary listing
NYSE
Employees
1,094
Headquarters
Website
Glaukos Metrics
BasicAdvanced
$9.8bn
-
-$3.25
0.75
-
Price and volume
Market cap
$9.8bn
Beta
0.75
52-week high
$184.00
52-week low
$73.16
Average daily volume
921k
Financial strength
Current ratio
5.04
Quick ratio
4.155
Long term debt to equity
15.068
Total debt to equity
15.766
Interest coverage (TTM)
-16.16%
Profitability
EBITDA (TTM)
-37.025
Gross margin (TTM)
79.12%
Net profit margin (TTM)
-30.68%
Operating margin (TTM)
-12.94%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-5.20%
Return on equity (TTM)
-25.98%
Valuation
Price to revenue (TTM)
15.762
Price to book
14.38
Price to tangible book (TTM)
20.08
Price to free cash flow (TTM)
-792.023
Free cash flow yield (TTM)
-0.13%
Free cash flow per share (TTM)
-0.21
Growth
Revenue change (TTM)
41.55%
Earnings per share change (TTM)
96.33%
3-year revenue growth (CAGR)
27.34%
10-year revenue growth (CAGR)
21.02%
3-year earnings per share growth (CAGR)
7.11%
10-year earnings per share growth (CAGR)
57.51%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Glaukos News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.